JP2005529938A - 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 - Google Patents

癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 Download PDF

Info

Publication number
JP2005529938A
JP2005529938A JP2004510709A JP2004510709A JP2005529938A JP 2005529938 A JP2005529938 A JP 2005529938A JP 2004510709 A JP2004510709 A JP 2004510709A JP 2004510709 A JP2004510709 A JP 2004510709A JP 2005529938 A JP2005529938 A JP 2005529938A
Authority
JP
Japan
Prior art keywords
free radical
sesquiterpene
iron
cancer
radical generator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004510709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529938A5 (enExample
Inventor
ヘンリー シー． ライ，
ナレンドラ ピー． シン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of JP2005529938A publication Critical patent/JP2005529938A/ja
Publication of JP2005529938A5 publication Critical patent/JP2005529938A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2004510709A 2002-06-06 2003-06-06 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 Pending JP2005529938A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38692802P 2002-06-06 2002-06-06
PCT/US2003/017791 WO2003103588A2 (en) 2002-06-06 2003-06-06 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer

Publications (2)

Publication Number Publication Date
JP2005529938A true JP2005529938A (ja) 2005-10-06
JP2005529938A5 JP2005529938A5 (enExample) 2006-06-22

Family

ID=29736235

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004510709A Pending JP2005529938A (ja) 2002-06-06 2003-06-06 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
JP2004510713A Expired - Fee Related JP4440768B2 (ja) 2002-06-06 2003-06-06 アルテミシニン関連エンドペルオキシダーゼと鉄保有タンパク質と間の共有結合コンジュゲート、および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004510713A Expired - Fee Related JP4440768B2 (ja) 2002-06-06 2003-06-06 アルテミシニン関連エンドペルオキシダーゼと鉄保有タンパク質と間の共有結合コンジュゲート、および使用方法

Country Status (11)

Country Link
US (2) US20040058981A1 (enExample)
EP (2) EP1531851B1 (enExample)
JP (2) JP2005529938A (enExample)
CN (3) CN1313145C (enExample)
AU (2) AU2003251405A1 (enExample)
BR (2) BR0312685A (enExample)
CA (2) CA2488347A1 (enExample)
NZ (2) NZ537114A (enExample)
RU (2) RU2004139090A (enExample)
WO (1) WO2003103588A2 (enExample)
ZA (1) ZA200500023B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523703A (ja) * 2005-10-20 2009-06-25 エピフアルマ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング アルテミシニン及びその誘導体を使用する良性色素性ホクロ（母斑）の処置及び予防
JP2012524772A (ja) * 2009-04-23 2012-10-18 ロンドンファーマ リミテッド ジヒドロアルテミシニンを含む舌下スプレー用製剤
US8522984B2 (en) 2009-05-07 2013-09-03 National University Corporation Okayama University Filter and air cleaner
JP2016500117A (ja) * 2012-11-29 2016-01-07 昆明制薬集団股▲分▼有限公司 アルテメーテル含有医薬組成物、製剤およびその使用
JP2021510715A (ja) * 2018-01-17 2021-04-30 セントジョージズ ホスピタル メディカル スクール 白血病治療のための併用療法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071506A1 (en) 2003-02-12 2004-08-26 Georgetown University Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
SI1675622T1 (sl) * 2003-09-17 2017-09-29 Nektar Therapeutics Večkraka polimerna predzdravila
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CN1255106C (zh) * 2003-09-26 2006-05-10 李国桥 复方青蒿素
US20050096369A1 (en) * 2003-11-04 2005-05-05 Hoang Ba X. Compositions and methods for treating cellular proliferation disorders
JP2007511600A (ja) * 2003-11-19 2007-05-10 ベクタ・リミテッド エンドペルオキシド架橋含有化合物を使用するヘリコバクター・ピロリ関連疾患の治療のための方法および組成物
CN1311832C (zh) * 2005-01-12 2007-04-25 四川科伦药业股份有限公司 溴代二氢青蒿素的医药用途
US20060270863A1 (en) * 2005-05-27 2006-11-30 Amyris Biotechnologies Conversion of amorpha-4,11-diene to artemisinin and artemisinin precursors
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
WO2007112451A2 (en) * 2006-03-28 2007-10-04 University Of Washington Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents
WO2008046109A2 (en) * 2006-10-13 2008-04-17 University Of Washington Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer
US8354549B2 (en) * 2006-11-30 2013-01-15 Nektar Therapeutics Method for preparing a polymer conjugate
RU2009133793A (ru) * 2007-02-09 2011-03-20 Энзон Фармасьютикалз, Инк. (Us) Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи
RU2515063C9 (ru) * 2008-01-30 2014-08-10 Пиерис АГ Мутеины липокалина слезной жидкости, обладающие аффинностью к с-мет рецепторной тирозинкиназе человека, и способы их получения
CN101323569B (zh) * 2008-07-24 2011-01-26 上海交通大学 倍半萜青蒿萜酯ae及其提取纯化方法
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
US20100056555A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
HRP20192120T1 (hr) 2008-09-23 2020-02-21 Nektar Therapeutics Postupak metronomskog doziranja kamptotecinskih prolijekova (e.g.peg-irinotekan)
CA2738807A1 (en) * 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
GB2469791B (en) * 2009-04-23 2011-12-14 Londonpharma Ltd Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
CN102399142B (zh) * 2010-09-14 2014-09-24 华北制药集团新药研究开发有限责任公司 一类倍半萜酯化合物及其制备方法和用途
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN102727522B (zh) * 2011-04-08 2013-09-25 石雁羽 由溴代双氢青蒿素和Fe2+剂组成的复方双释胶囊制剂
CN103405779B (zh) * 2013-07-18 2015-09-30 江苏省血吸虫病防治研究所 一种预防血吸虫感染长效青蒿琥酯药物及其制备方法
CN109908137B (zh) * 2019-03-11 2022-02-18 江苏省人民医院（南京医科大学第一附属医院） 青蒿素在杀伤乳腺癌干细胞的药物中的应用
CN114983999A (zh) * 2022-06-09 2022-09-02 四川大学 一种青蒿素及其衍生物的新用途、验证方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
WO1997001548A1 (en) * 1995-06-29 1997-01-16 Hauser Chemical Research, Inc. Artemisinin dimer compounds having anticancer activity
WO1999065914A1 (fr) * 1998-06-17 1999-12-23 Shanghai Institute Of Materia Medica Derives de l'artemisinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000042046A1 (en) * 1999-01-12 2000-07-20 Hauser, Inc. Artemisinin analogs having antimalarial, antiproliferative, and antitumor activities and chemoselective methods of making the same
WO2001004123A2 (en) * 1999-07-09 2001-01-18 Ufc Limited Peroxide-based antimalarial compounds
JP2001527043A (ja) * 1997-12-30 2001-12-25 ハウサー，インコーポレイティド 抗マラリア、抗増殖及び抗腫瘍活性を有する、ｃ−１０炭素原子−置換されているアルテミシニン様トリオキサン化合物類
JP2002128784A (ja) * 2000-10-25 2002-05-09 Japan Science & Technology Corp 細胞侵入型励起一重項酸素発生化合物および該化合物を含む薬剤類

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916204A (en) * 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
FR2630329B1 (fr) * 1988-04-20 1991-07-05 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
RU2098407C1 (ru) * 1989-09-27 1997-12-10 Рон-Пуленк Рорер С.А. Способ получения пероксиацетальлактонового соединения (варианты) и лактон
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5472684A (en) * 1993-06-02 1995-12-05 Colgate Palmolive Company Oral compositions for plaque and gingivitis
US5869310A (en) * 1996-06-03 1999-02-09 Promega Corporation Isolated agarase enzyme from flavobacterium sp. strain NR19, cloned genes therefor, and expression thereof in transformed host cells
US6127405A (en) * 1998-07-10 2000-10-03 Council Of Scientific And Industrial Research Method for the use of alpha arteether as an anti-bacterial and anti-fungal agent
IN191696B (enExample) * 1999-02-12 2003-12-20 Council Scient Ind Res
WO2002091992A2 (en) * 2001-05-16 2002-11-21 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
WO1997001548A1 (en) * 1995-06-29 1997-01-16 Hauser Chemical Research, Inc. Artemisinin dimer compounds having anticancer activity
JP2001527043A (ja) * 1997-12-30 2001-12-25 ハウサー，インコーポレイティド 抗マラリア、抗増殖及び抗腫瘍活性を有する、ｃ−１０炭素原子−置換されているアルテミシニン様トリオキサン化合物類
WO1999065914A1 (fr) * 1998-06-17 1999-12-23 Shanghai Institute Of Materia Medica Derives de l'artemisinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000042046A1 (en) * 1999-01-12 2000-07-20 Hauser, Inc. Artemisinin analogs having antimalarial, antiproliferative, and antitumor activities and chemoselective methods of making the same
WO2001004123A2 (en) * 1999-07-09 2001-01-18 Ufc Limited Peroxide-based antimalarial compounds
JP2002128784A (ja) * 2000-10-25 2002-05-09 Japan Science & Technology Corp 細胞侵入型励起一重項酸素発生化合物および該化合物を含む薬剤類

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523703A (ja) * 2005-10-20 2009-06-25 エピフアルマ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング アルテミシニン及びその誘導体を使用する良性色素性ホクロ（母斑）の処置及び予防
JP2012524772A (ja) * 2009-04-23 2012-10-18 ロンドンファーマ リミテッド ジヒドロアルテミシニンを含む舌下スプレー用製剤
US8522984B2 (en) 2009-05-07 2013-09-03 National University Corporation Okayama University Filter and air cleaner
JP2016500117A (ja) * 2012-11-29 2016-01-07 昆明制薬集団股▲分▼有限公司 アルテメーテル含有医薬組成物、製剤およびその使用
JP2021510715A (ja) * 2018-01-17 2021-04-30 セントジョージズ ホスピタル メディカル スクール 白血病治療のための併用療法

Also Published As

Publication number Publication date
EP1553935A2 (en) 2005-07-20
WO2003103588A3 (en) 2004-04-15
JP2005535606A (ja) 2005-11-24
ZA200500023B (en) 2005-10-20
EP1553935A4 (en) 2010-07-07
US20040058981A1 (en) 2004-03-25
CN1313145C (zh) 2007-05-02
EP1531851A2 (en) 2005-05-25
CA2488347A1 (en) 2003-12-18
CN1668323A (zh) 2005-09-14
NZ537114A (en) 2007-02-23
BR0311627A (pt) 2005-08-30
AU2003243418B2 (en) 2009-02-19
JP4440768B2 (ja) 2010-03-24
WO2003103588A2 (en) 2003-12-18
AU2003251405A1 (en) 2003-12-22
AU2003243418A1 (en) 2003-12-22
EP1531851B1 (en) 2011-12-14
BR0312685A (pt) 2005-09-06
RU2004139090A (ru) 2005-06-10
CN101843904A (zh) 2010-09-29
CN1668293A (zh) 2005-09-14
RU2004139096A (ru) 2005-06-10
US20080119542A1 (en) 2008-05-22
NZ537113A (en) 2007-01-26
EP1531851A4 (en) 2007-12-12
CA2488360A1 (en) 2003-12-18
RU2325156C2 (ru) 2008-05-27

Similar Documents

Publication Publication Date Title
JP2005529938A (ja) 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
AU2007203159B2 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
RS20060149A (sr) Farmaceutski preparat koji sadrži i.a. vitamin c,magnezijum, ekstrakt zelenog čaja za usporavanje kardiovaskularnih bolesti
Zou et al. Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction
US7115563B2 (en) Composition and its therapeutic use
JP2002542191A (ja) グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物
KR101425303B1 (ko) 이소플라본을 포함하는 관절염 예방 및 치료용 약학적 조성물
EP3741366A1 (en) Composition comprising dunnione as effective ingredient for prevention or alleviation of hair loss
US9029419B2 (en) Use of zinc N-acetyltaurinate
JP6441364B2 (ja) ジベンゾ−アルファ−ピロンを用いた体重増加制御
JPH06199694A (ja) 血圧安定化治療剤
ZA200500027B (en) Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer.
US20050119301A1 (en) Treatment of restenosis
JPH11501011A (ja) 神経保護薬としての縮合ベンゾチアゾール類の利用
US20100292186A1 (en) Pharmaceutical Composition for Treatment or Prevention of Liver Cancer
HK40084623A (en) Use of glycerol phospholipids in the prevention and treatment of hyperlipidemia, atherosclerosis, non-alcoholic fatty liver and obesity
KR20060072603A (ko) α-리포산 함유 간질환 예방 또는 치료용 조성물
CN118985926A (zh) 一种具有改善线粒体功能的营养组合物及其应用
AU2008200518B2 (en) Treatment of restenosis
CN119258110A (zh) 用于防止和逆转在人体内的氧化应激期间的蛋白质糖化的微量营养素组合物
WO2022005848A1 (en) Combinations of carnosine and zinc for the treatment and prevention of viral infections
KR20050082448A (ko) 테트라하이드로베르베린을 유효성분으로 함유하는함유하는 동맥경화증, 고지혈증 및 간 질환의 예방 및치료용 조성물
KR19980066916A (ko) 간장의 항섬유화 작용을 가지는 약학적 조성물
MXPA97004669A (en) Use of nebivolol as an antiaterogen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100622